Regkirona (regdanvimab) Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to emergency authorization of COVID-19 antibody therapies, rapid scale-up of biologic production, expansion of hospital-based covid treatment, increased government procurement programs, growth of infectious disease clinical infrastructure.

The growth in the forecast period can be attributed to ongoing demand for antiviral preparedness, expansion of monoclonal antibody platforms, increasing focus on immunocompromised patient protection, rising investments in pandemic response infrastructure, development of next-generation antiviral antibodies. Major trends in the forecast period include increasing use of monoclonal antibodies in infectious diseases, rising focus on early COVID-19 intervention, growing integration with hospital treatment protocols, expansion of pandemic preparedness therapeutics, enhanced emphasis on high-risk patient protection.

The increasing awareness of personalized medicine is expected to drive the growth of the Regkirona (regdanvimab) market in the future. Personalized medicine is a healthcare approach that customizes treatment plans based on an individual's genetic, environmental, and lifestyle factors, aiming to enhance treatment effectiveness and reduce side effects. The growing awareness of personalized medicine is supported by advancements in genomics, improved diagnostic technologies, increased public and healthcare sector support, and the rising demand for treatments that are tailored to individual needs for better patient outcomes. Regkirona contributes to personalized medicine by offering a targeted treatment for COVID-19 based on specific patient characteristics, such as disease severity and risk factors. For example, in February 2024, the Personalized Medicine Coalition, a US-based organization, reported that in 2023, the FDA approved 16 new personalized treatments for rare diseases, a significant increase from the six approvals in 2022. As a result, the rising awareness of personalized medicine is expected to further fuel the growth of the Regkirona (regdanvimab) market.

The increasing focus on therapeutics for immunocompromised patients is also expected to drive the growth of the Regkirona (regdanvimab) market. Therapeutics for immunocompromised patients are treatments designed to offer direct clinical protection to individuals with weakened immune systems. The growing focus on these therapeutics is due to the rising global population of individuals with clinically significant immune suppression, leading to a larger cohort of patients who require direct-acting therapeutic protection when vaccines provide limited benefit. Regkirona (regdanvimab) aligns with this rising focus by offering rapid, passive antibody-based protection, which reduces the dependence on endogenous immune responses that are often insufficient despite vaccination. For instance, in December 2024, the CDC, a U.S.-based public health agency, reported that approximately 6% of U.S. adults have an immunocompromising condition, and 16% of COVID-19 hospitalizations between July 2023 and May 2024 occurred among immunocompromised individuals. As a result, the growing demand for therapeutics in this high-risk population is expected to drive the uptake of Regkirona and contribute to market growth.

Major companies operating in the Regkirona (regdanvimab) market are focusing on technological advancements, such as inhalation-based antibody delivery, to gain a competitive edge. Inhalation-based antibody delivery involves administering monoclonal antibodies via aerosol or nebulizer, allowing the medication to be directly deposited into the respiratory tract rather than through systemic infusion. For example, in March 2024, the U.S.-based biopharma company Inhalon Biopharma launched IN 006, a nebulized formulation of regdanvimab. In a Phase 1b trial, this formulation demonstrated uniform distribution across the lungs and achieved antibody concentrations in the respiratory tract that were up to 20 times higher than intravenously delivered regdanvimab, while requiring a 90% lower systemic dose. This method offers the potential for higher local potency and reduced systemic exposure, although it may present challenges related to manufacturing complexity and stability.

Major companies operating in the regkirona (regdanvimab) market are Celltrion Inc.

North America was the largest region in the regkirona (regdanvimab) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the regkirona (regdanvimab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the regkirona (regdanvimab) market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are influencing the regkirona market by increasing costs of imported monoclonal antibody production materials, viral filtration systems, single-use bioprocessing components, and cold-chain distribution equipment. Asia-Pacific and Europe are most affected due to cross-border biologics manufacturing dependencies, while North America faces higher costs in emergency stockpiling and hospital distribution. These tariffs increase treatment acquisition costs and impact public health procurement budgets. However, they are also supporting regional biologics capacity building, domestic antibody production, and long-term preparedness for future infectious disease outbreaks.

The regkirona (regdanvimab) market research report is one of a series of new reports that provides regkirona (regdanvimab) market statistics, including regkirona (regdanvimab) industry global market size, regional shares, competitors with a regkirona (regdanvimab) market share, detailed regkirona (regdanvimab) market segments, market trends and opportunities, and any further data you may need to thrive in the regkirona (regdanvimab) industry. This regkirona (regdanvimab) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Regkirona, also known as regdanvimab, is a monoclonal antibody treatment for COVID-19 designed to prevent the progression of mild to moderate symptoms in high-risk patients. It works by binding to the spike protein of SARS-CoV-2, blocking the virus from entering human cells and inhibiting replication.

The primary clinical indications for Regkirona (regdanvimab) include mild-to-moderate COVID-19, severe COVID-19, prevention of COVID-19 progression, and post-exposure prophylaxis. Mild-to-moderate COVID-19 refers to cases with symptoms such as fever, cough, and fatigue that can be managed at home, with moderate cases involving some shortness of breath but not requiring intensive medical care. Regkirona is distributed through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies, and is available to a broad range of end users, including pediatric, adult, and geriatric populations.

The regkirona (regdanvimab) market consists of sales of products including injections, dosage vials, pre-filled syringes, emergency use authorization kits, and co-packaged products. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.